MORA, BARBARA
 Distribuzione geografica
Continente #
NA - Nord America 2.058
EU - Europa 909
AS - Asia 203
SA - Sud America 6
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.179
Nazione #
US - Stati Uniti d'America 2.057
IT - Italia 502
UA - Ucraina 137
SE - Svezia 101
TR - Turchia 87
IE - Irlanda 67
VN - Vietnam 62
CN - Cina 40
DE - Germania 38
GB - Regno Unito 26
FI - Finlandia 12
NL - Olanda 5
FR - Francia 4
JP - Giappone 4
BE - Belgio 3
CL - Cile 3
ES - Italia 3
TH - Thailandia 3
BD - Bangladesh 2
BR - Brasile 2
GR - Grecia 2
HU - Ungheria 2
PL - Polonia 2
AL - Albania 1
AR - Argentina 1
AT - Austria 1
AU - Australia 1
CA - Canada 1
EU - Europa 1
HK - Hong Kong 1
IN - India 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RO - Romania 1
SA - Arabia Saudita 1
SG - Singapore 1
Totale 3.179
Città #
Milan 371
Fairfield 323
Woodbridge 226
Ashburn 181
Houston 162
Chandler 150
Seattle 149
Jacksonville 121
Wilmington 121
Cambridge 116
Ann Arbor 113
Nyköping 77
Princeton 65
Dublin 64
Izmir 48
Dearborn 38
Dong Ket 33
San Diego 31
Rome 22
Ogden 20
Como 18
Redmond 18
Kocaeli 13
London 10
Washington 8
Beijing 6
New York 5
Boardman 4
Kilburn 4
Kunming 4
Redwood City 4
San Francisco 4
Amsterdam 3
Brussels 3
Chicago 3
Frankfurt am Main 3
Hefei 3
Nanchang 3
Nanjing 3
Norwalk 3
San Jose 3
Busto Arsizio 2
Dhaka 2
Hanoi 2
Mountain View 2
Piombino 2
Prescot 2
Seriate 2
Shanghai 2
Tokyo 2
Vanzaghello 2
Zhengzhou 2
Abbadia Lariana 1
Bangkok 1
Baotou 1
Budapest 1
Casorezzo 1
Central 1
Chaoyang 1
Charleston 1
Charlotte 1
Chisinau 1
Chiswick 1
Cupertino 1
Fayetteville 1
Fiesole 1
Fuzhou 1
Gavirate 1
Genoa 1
Graz 1
Greenwich 1
Guangzhou 1
Guiyang 1
Gurgaon 1
Harbin 1
Hebei 1
Helsinki 1
Hounslow 1
Huzhou 1
Inglewood 1
Kuala Lumpur 1
Lappeenranta 1
Leawood 1
Los Angeles 1
Madrid 1
Miami Beach 1
New Bedfont 1
Ningbo 1
Oslo 1
Palermo 1
Riyadh 1
Rozzano 1
San Mateo 1
Shaoxing 1
Singapore 1
São Paulo 1
Tirana 1
Toronto 1
Trieste 1
Valladolid 1
Totale 2.626
Nome #
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts 182
Looking for CALR mutations in familial myeloproliferative neoplasms 170
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 156
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 148
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 142
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion 142
It is time to change thrombosis risk assessment for PV and ET? 141
Developments in diagnosis and treatment of essential thrombocythemia 137
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group 137
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients 135
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms 124
Prognostication in myelofi-brosis 122
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis 116
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 111
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia 105
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 96
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation 92
Therapy of polycythemia vera: Is it time to change? 91
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches 86
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 85
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 68
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses 67
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection 67
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi 64
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma 54
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence 50
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 49
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis 48
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 47
Is there a gender effect in polycythemia vera? 45
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients 45
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 43
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 42
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 36
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 29
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 1
Totale 3.273
Categoria #
all - tutte 13.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.630


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019157 0 0 0 0 0 0 0 0 0 0 61 96
2019/2020624 22 25 30 114 48 73 95 75 62 34 16 30
2020/2021782 22 48 116 46 114 65 42 63 75 56 62 73
2021/2022331 50 16 2 15 11 22 16 21 26 87 19 46
2022/2023473 33 13 75 43 36 102 2 56 75 13 9 16
2023/2024606 91 94 92 115 133 40 7 4 25 2 3 0
Totale 3.273